On 22 September 2026, Oncoinvent ASA ("Oncoinvent" or the "Company") announced the successful completion of a private placement and a retail offering, raising gross proceeds of approximately NOK 149 million through the allocation of 1,650,000 new shares at a subscription price of NOK 90 per share. The transaction was supported by the Company's largest shareholders, Linc and Hadean Ventures, and multiple existing and new Norwegian and international investors.
The net proceeds from the equity issue will enable the Company to progress the ongoing Phase 2 study beyond a more mature interim readout in March / April 2027, complete recruitment for the Phase 2 study, expected during H1 2027, deliver regulatory alignment with the FDA and EMA, culminating in Phase 3 IND / CTA submission, and advance Phase 3 readiness and early start-up activities.
ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in connection with the equity raise. We congratulate Oncoinvent on the successful financing and would like to extend our gratitude for the vote of confidence.